Treatment of meningeal neoplasms.
D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy*; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D002404:Catheterization / Q000009:adverse effects; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D006801:Humans; D007276:Injections, Intraventricular; D007278:Injections, Spinal; D007938:Leukemia / Q000188:drug therapy; D008161:Lumbosacral Region; D008578:Meninges; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D051381:Rats; D013120:Spinal Cord Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D003561:Cytarabine; D008727:Methotrexate